Merck donates half a million dollars to combat maternal mortality in Haiti

Merck donates half a million dollars to combat maternal mortality in Haiti 
KIRKLAND, QC, Nov. 12, 2012 /CNW Telbec/ - Merck is pleased to announce a 
grant of $500,000 to the Centre de coopération internationale en santé et 
développement (Center for International Cooperation in Health and Development 
or CCISD) based in Quebec City. The donation is part of Merck for Mothers 
Global Giving Program which aims to support philanthropic organizations that 
are dedicated to improving maternal health and, ultimately, help reduce the 
number of women who die or suffer disabilities from pregnancy and 
childbirth-related complications. Approximately 20 projects were chosen around 
the world, including CCISD which will be directing the funds towards a 
maternal health project targeting the Artibonite communities of Anse Rouge, 
Terre Neuve and Ennery in Haiti. 
"We are very pleased to be supporting CCISD's new program aimed at 
strengthening maternal health services in Haiti," said Cyril Schiever, 
President and Managing Director of Merck Canada Inc. "CCISD does impressive 
work around the world promoting both primary care and women's health and 
aligns perfectly with the objectives of the Merck for Mothers program, which 
is dedicated to creating a world where no woman has to die from complications 
of pregnancy and childbirth." 
The CCISD has been implementing international health projects for over 25 
years. Starting in January 2013, they will direct the Merck for Mothers grant 
to a project complementary to their 'Integrated Management of Maternal and 
Child Health' program - also known as PRISMA - in the Artibonite region in 
Haiti. "Haiti has the highest maternal mortality rate in the northern 
hemisphere(1). Funding to provide access to services and medical supplies is 
essential to help save lives in this country," said Robert Beaudry, Executive 
Director of CCISD. "Of all those burdened with the lack of access to proper 
healthcare, some of the saddest stories are about the preventable deaths of 
mothers and newborns." 
According to Martine Bernier, Project Director of the PRISMA program in Haiti, 
"Only in the intervention area of the project that will be supported by the 
Merck for Mothers grant, over 1,600 women become pregnant every year. The cost 
and accessibility of prenatal and delivery services can be huge obstacles to 
Haitian mothers. This much-needed donation will help provide better access to 
services and, ultimately, lower the complications and mortality rates of women 
and newborns in this area." 
About Merck for Mothers 
Over the next decade, it is estimated that nearly three million women will die 
from complications due to pregnancy and childbirth globally. The majority of 
these deaths are preventable. When a woman dies, the ripple effect on families 
and communities is enormous. Her baby is more likely to die before the age of 
two and her other children are more likely to leave school, suffer from poor 
health, and die prematurely. 
Merck for Mothers is a 10-year, half-billion-dollar initiative to create a 
world where no woman has to die from complications of pregnancy and 
childbirth. Drawing on the company's history of discovering innovative, 
life-saving medicines and vaccines, Merck for Mothers is applying the 
company's scientific and business expertise to reduce maternal mortality 
around the world. 
In order to achieve our goals, our approach focuses on three main pillars: 
product innovation, accelerating access to maternal health solutions and 
services, as well as advocacy and awareness. 
The Merck for Mothers Global Giving Programwill focus on helping countries 
reduce maternal mortality and improve maternal health with the overall aim of 
supporting the United Nations Millennium Development Goal (MDG) 5, which calls 
for a 75% reduction in maternal mortality and universal access to reproductive 
health by 2015. 
For more information, please visit 
About Merck
Today's Merck is a global healthcare leader working to help the world be well. 
Merck is known as MSD outside the United States and Canada. Through our 
medicines, vaccines, biologic therapies, and consumer and animal products, we 
work with customers and operate in more than 140 countries to deliver 
innovative health solutions. We also demonstrate our commitment to increasing 
access to healthcare through far-reaching policies, programs and partnerships. 
For more information about our operations in Canada, visit 
Forward Looking Statement
This news release includes "forward-looking statements" within the meaning of 
the safe harbor provisions of the United States Private Securities Litigation 
Reform Act of 1995. Such statements may include, but are not limited to, 
statements about the benefits of the merger between Merck and Schering-Plough, 
including future financial and operating results, the combined company's 
plans, objectives, expectations and intentions and other statements that are 
not historical facts. Such statements are based upon the current beliefs and 
expectations of Merck's management and are subject to significant risks and 
uncertainties. Actual results may differ from those set forth in the 
forward-looking statements. 
The following factors, among others, could cause actual results to differ from 
those set forth in the forward-looking statements: the possibility that all of 
the expected synergies from the merger of Merck and Schering-Plough will not 
be realized, or will not be realized within the expected time period; the 
impact of pharmaceutical industry regulation and health care legislation in 
the United States and internationally; Merck's ability to accurately predict 
future market conditions; dependence on the effectiveness of Merck's patents 
and other protections for innovative products; and the exposure to litigation 
and/or regulatory actions. Merck undertakes no obligation to publicly update 
any forward-looking statement, whether as a result of new information, future 
events or otherwise. Additional factors that could cause results to differ 
materially from those described in the forward-looking statements can be found 
in Merck's 2011 Annual Report on Form 10-K and the company's other filings 
with the Securities and Exchange Commission (SEC) available at the SEC's 
Internet site ( 
(1 )Médecins sans frontières, 2012. MSF in Haiti. Accessible en ligne : 
(consulté en octobre 2012) 
Attachment: PHOTO and caption   
Media Contacts: Ani Armenian Merck 514-428-3395  Valérie Diamant 
CCISD 418-656-5525 ext. 8319  Québec/Montréal Sylvie Patry/Roch 
Landriault 418-648-1233 ext. 232/514-843-2345 
Image with caption: "Jennifer Chan, Vice-President, Communications and Policy, 
Merck Canada; Robert Beaudry, Executive Director, CCISD and Martine Bernier, 
Project Director of the PRISMA program in Haiti. (CNW Group/MERCK)". Image 
available at: 
To view this news release in HTML formatting, please use the following URL: 
CO: Center for International Cooperation in Health and Development (CCISD)
ST: Quebec
-0- Nov/12/2012 22:26 GMT
Press spacebar to pause and continue. Press esc to stop.